Vertex Pharmaceuticals Incorporated Company Profile (NASDAQ:VRTX)

About Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Vertex Pharmaceuticals Incorporated logoVertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:VRTX
  • CUSIP: 92532F10
  • Web: www.vrtx.com
Capitalization:
  • Market Cap: $40.7 billion
  • Outstanding Shares: 249,068,000
Average Prices:
  • 50 Day Moving Avg: $132.39
  • 200 Day Moving Avg: $108.69
  • 52 Week Range: $71.46 - $167.00
P/E:
  • Trailing P/E Ratio: 226.14
  • Foreward P/E Ratio: 51.23
  • P/E Growth: 1.48
Sales & Book Value:
  • Annual Revenue: $2.02 billion
  • Price / Sales: 20.15
  • Book Value: $6.03 per share
  • Price / Book: 27.10
Profitability:
  • EBIDTA: $356.32 million
  • Net Margins: 8.64%
  • Return on Equity: 3.00%
  • Return on Assets: 1.47%
Debt:
  • Debt-to-Equity Ratio: 0.02%
  • Current Ratio: 3.82%
  • Quick Ratio: 3.65%
Misc:
  • Average Volume: 2.08 million shs.
  • Beta: 1.74
  • Short Ratio: 1.89
 
Frequently Asked Questions for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

What is Vertex Pharmaceuticals Incorporated's stock symbol?

Vertex Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "VRTX."

How were Vertex Pharmaceuticals Incorporated's earnings last quarter?

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings data on Thursday, April, 27th. The company reported $0.13 EPS for the quarter, topping the consensus estimate of $0.04 by $0.09. The firm earned $714.72 million during the quarter, compared to analyst estimates of $692.64 million. Vertex Pharmaceuticals Incorporated had a return on equity of 3.00% and a net margin of 8.64%. Vertex Pharmaceuticals Incorporated's revenue was up 79.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.09 EPS. View Vertex Pharmaceuticals Incorporated's Earnings History.

When will Vertex Pharmaceuticals Incorporated make its next earnings announcement?

Vertex Pharmaceuticals Incorporated is scheduled to release their next quarterly earnings announcement on Wednesday, July, 26th 2017. View Earnings Estimates for Vertex Pharmaceuticals Incorporated.

Where is Vertex Pharmaceuticals Incorporated's stock going? Where will Vertex Pharmaceuticals Incorporated's stock price be in 2017?

24 brokers have issued 1 year price objectives for Vertex Pharmaceuticals Incorporated's stock. Their predictions range from $81.00 to $200.00. On average, they anticipate Vertex Pharmaceuticals Incorporated's share price to reach $157.04 in the next year. View Analyst Ratings for Vertex Pharmaceuticals Incorporated.

What are analysts saying about Vertex Pharmaceuticals Incorporated stock?

Here are some recent quotes from research analysts about Vertex Pharmaceuticals Incorporated stock:

  • 1. According to Zacks Investment Research, "Vertex has two CF drugs – Kalydeco & Orkambi – in its portfolio with blockbuster potential. Its efforts to get the drugs approved for additional indications are encouraging. Label expansion will increase the patient population and boost sales. Vertex’s CF pipeline is quite strong with a broad portfolio of next-generation CF correctors. Investor focus will now be on the triple combination CF regimens, which are crucial for long-term growth at Vertex. Multiple triple combo data readouts in CF patients are expected in 2H17. The stock has also done well this year. However, Vertex has faced many challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles and a slower-than-anticipated uptake in Germany. Estimates have also gone up slightly ahead of the company’s Q2 earnings release. The company has a positive record of earnings surprises in recent quarters." (7/4/2017)
  • 2. Needham & Company LLC analysts commented, "Vertex announced 1Q17 financial results last night. Orkambi WW sales $295M beat our $277.5M and consensus $280M ests. Kalydeco WW sales $186M beat our $178.0M and consensus $175M ests. Mgmt raised Kalydeco, but left unch Orkambi guidance ($1.1-1.3B Orkambi and $710M-$730M from $690-710M Kalydeco). Orkambi driven by strong uptake and compliance in pediatric pts and Kalydeco driven by one time reimbursement in Europe. Our 2Q17 Orkambi and Kalydeco ests are $294.0M (was $287.5M) and $179.0M (was $178.0M). Stock reflects IVA/ TEZ commercial success and we maintain HOLD." (4/28/2017)
  • 3. Maxim Group analysts commented, "Vertex reported 1Q17 with total CF revenue of $481M, which was above consensus of $444M, driven by both Orkambi and Kalydeco revenues beating estimates." (4/28/2017)
  • 4. BMO Capital Markets analysts commented, "We believe Vertex's acquisition of Concert's CTP-656, a deuterated ivacaftor (Kalydeco), removes a key potential competitor in the cystic fibrosis space. In addition, CTP-656 could replace Kalydeco in the triple combo, allowing a once-daily (QD) regimen, which would offset an important advaVertex Pharma (NASDAQ: VRTX)ntage of Galapagos's QD triple combo in development. We also believe CTP-656's later patent expiration date (2032 vs. 2027 for Kalydeco) will be an important lifecycle management component of Vertex's cystic fibrosis franchise." (3/7/2017)
  • 5. Robert W. Baird analysts commented, "Vertex announced plans to acquire Concert Pharmaceuticals' CTP-656, or deuterated ivacaftor. We think this acquisition highlights Vertex's commitment to defending its position as the leading CF company as it both eliminates a potential competitor and allows access to a once-daily modified version of ivacaftor with a longer patent life than ivacaftor itself. Overall, we think this is a smart deal for the company at a reasonable price, and reiterate our Outperform rating." (3/6/2017)

Who are some of Vertex Pharmaceuticals Incorporated's key competitors?

Who are Vertex Pharmaceuticals Incorporated's key executives?

Vertex Pharmaceuticals Incorporated's management team includes the folowing people:

  • Jeffrey M. Leiden M.D. Ph.D., Chairman of the Board, President, Chief Executive Officer
  • Ian F. Smith CPA, Chief Financial Officer, Chief Operating Officer, Executive Vice President
  • Michael J. Parini J.D., Executive Vice President, Chief Legal and Administrative Officer
  • David Altshuler M.D., Ph.D., Executive Vice President - Global Research, Chief Scientific Officer
  • Stuart A. Arbuckle, Executive Vice President, Chief Commercial Officer
  • Jeffrey A. Chodakewitz M.D., Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
  • Amit K. Sachdev J.D., Executive Vice President, Chief Regulatory Officer and Chief of Staff to the CEO
  • Paul M. Silva, Senior Vice President, Corporate Controller
  • Bruce I. Sachs, Lead Director, Independent Director
  • Elaine S. Ullian, Co-Lead Independent Director

Who owns Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Advisors LLC (0.65%), Public Employees Retirement Association of Colorado (0.21%), Strs Ohio (0.14%), AMF Pensionsforsakring AB (0.13%), Atalanta Sosnoff Capital LLC (0.12%) and Chevy Chase Trust Holdings Inc. (0.10%). Company insiders that own Vertex Pharmaceuticals Incorporated stock include Amit Sachdev, David Altshuler, Elaine Ullian, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia, Stuart A Arbuckle and Yuchun Lee. View Institutional Ownership Trends for Vertex Pharmaceuticals Incorporated.

Who sold Vertex Pharmaceuticals Incorporated stock? Who is selling Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Advisors LLC, APG Asset Management N.V., Factory Mutual Insurance Co., Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Capstone Asset Management Co., Hartford Investment Management Co. and Shell Asset Management Co.. Company insiders that have sold Vertex Pharmaceuticals Incorporated stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Joshua S Boger, Michael Parini, Paul M Silva, Sangeeta N Bhatia and Stuart A Arbuckle. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

Who bought Vertex Pharmaceuticals Incorporated stock? Who is buying Vertex Pharmaceuticals Incorporated stock?

Vertex Pharmaceuticals Incorporated's stock was acquired by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Acadian Asset Management LLC, Russell Investments Group Ltd., Bank of Montreal Can, Mn Services Vermogensbeheer B.V., Cullinan Associates Inc., Oakbrook Investments LLC and National Pension Service. View Insider Buying and Selling for Vertex Pharmaceuticals Incorporated.

How do I buy Vertex Pharmaceuticals Incorporated stock?

Shares of Vertex Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Vertex Pharmaceuticals Incorporated's stock price today?

One share of Vertex Pharmaceuticals Incorporated stock can currently be purchased for approximately $163.42.


MarketBeat Community Rating for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
Community Ranking:  3.3 out of 5 (  )
Outperform Votes:  923 (Vote Outperform)
Underperform Votes:  492 (Vote Underperform)
Total Votes:  1,415
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Hold Ratings, 21 Buy Ratings
Consensus Rating:Buy (Score: 2.88)
Consensus Price Target: $157.04 (3.90% downside)

Analysts' Ratings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/22/2017Morgan StanleyReiterated RatingOverweight$153.00 -> $190.00LowView Rating Details
7/21/2017Robert W. BairdReiterated RatingOutperform$136.00 -> $171.00LowView Rating Details
7/21/2017Needham & Company LLCReiterated RatingBuy$155.00 -> $195.00LowView Rating Details
7/21/2017BMO Capital MarketsReiterated RatingOutperform$132.00 -> $180.00LowView Rating Details
7/21/2017Citigroup Inc.Reiterated RatingBuy$135.00 -> $190.00LowView Rating Details
7/19/2017J P Morgan Chase & CoSet Price TargetBuy$129.00 -> $175.00LowView Rating Details
7/19/2017Maxim GroupSet Price TargetBuy$143.00 -> $195.00LowView Rating Details
7/19/2017Credit Suisse GroupBoost Price TargetOutperform$125.00 -> $195.00HighView Rating Details
7/19/2017JMP SecuritiesReiterated RatingOutperformHighView Rating Details
7/19/2017Raymond James Financial, Inc.UpgradeMarket Perform -> Outperform$181.00HighView Rating Details
7/19/2017Piper Jaffray CompaniesBoost Price TargetOverweight$194.00HighView Rating Details
7/19/2017Jefferies Group LLCReiterated RatingBuy$155.00 -> $185.00HighView Rating Details
7/19/2017HC WainwrightReiterated RatingHold$85.00HighView Rating Details
7/19/2017Janney Montgomery ScottUpgradeNeutral -> Buy$98.00HighView Rating Details
7/19/2017Cowen and CompanyUpgradeMarket Perform -> Outperform$105.00 -> $200.00HighView Rating Details
7/19/2017Barclays PLCUpgradeEqual Weight -> Overweight$115.00 -> $180.00HighView Rating Details
7/18/2017Stifel NicolausBoost Price TargetBuy -> Buy$130.00 -> $154.00HighView Rating Details
6/22/2017Leerink SwannReiterated RatingOutperformMediumView Rating Details
6/2/2017CIBCUpgradeMarket Perform -> OutperformLowView Rating Details
6/2/2017Oppenheimer Holdings, Inc.UpgradeMarket Perform -> Outperform$150.00MediumView Rating Details
5/19/2017Bank of America CorporationReiterated RatingNeutral$121.00 -> $125.00LowView Rating Details
3/14/2017ArgusReiterated RatingBuy$115.00 -> $92.95LowView Rating Details
11/1/2016William BlairDowngradeOutperform -> Market Perform$105.00 -> $81.00N/AView Rating Details
10/12/2016Royal Bank Of CanadaReiterated RatingBuyN/AView Rating Details
4/28/2016Goldman Sachs Group, Inc. (The)DowngradeBuy -> Neutral$109.00 -> $88.00N/AView Rating Details
3/28/2016GuggenheimLower Price TargetBuy$145.00 -> $114.00N/AView Rating Details
9/15/2015NomuraInitiated CoverageBuy$162.00N/AView Rating Details
7/31/2015Deutsche Bank AGReiterated RatingBuy$155.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Earnings History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017        
4/27/2017Q1 2017$0.04$0.13$692.64 million$714.72 millionViewN/AView Earnings Details
1/25/2017Q4 2016$0.29$0.35$453.40 million$458.71 millionViewN/AView Earnings Details
10/25/2016Q316$0.18$0.16$423.53 million$413.78 millionViewListenView Earnings Details
7/27/2016Q216$0.21$0.24$428.08 million$431.61 millionViewListenView Earnings Details
4/27/2016Q116$0.29$0.09$439.94 million$398.10 millionViewListenView Earnings Details
1/27/2016Q4$0.17$0.17$406.30 million$417.94 millionViewListenView Earnings Details
10/28/2015Q315($0.60)($0.13)$245.84 million$309.82 millionViewListenView Earnings Details
7/29/2015Q215($0.58)($0.54)$149.49 million$166.00 millionViewListenView Earnings Details
4/29/2015Q115($0.75)($0.62)$142.38 million$138.51 millionViewListenView Earnings Details
1/28/2015Q414($0.65)($0.55)$137.50 million$144.56 millionViewListenView Earnings Details
10/28/2014Q314($0.62)($0.37)$146.20 million$179.00 millionViewN/AView Earnings Details
7/29/2014Q214($0.71)($0.61)$131.85 million$138.42 millionViewListenView Earnings Details
5/1/2014Q114($0.68)($0.65)$134.46 million$118.50 millionViewN/AView Earnings Details
1/29/2014Q413($0.49)($0.56)$221.08 million$351.20 millionViewListenView Earnings Details
10/29/2013Q413($0.33)($0.32)$278.80 million$222.00 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.18)($0.26)$308.02 million$310.80 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.06)$0.03$307.85 million$328.40 millionViewN/AView Earnings Details
1/29/2013Q4 2012($0.07)($0.35)$318.53 million$334.00 millionViewN/AView Earnings Details
11/1/2012Q312$0.34$0.13$377.14 million$336.00 millionViewN/AView Earnings Details
7/30/2012$0.68$0.46ViewN/AView Earnings Details
4/26/2012$0.57$0.43ViewN/AView Earnings Details
2/2/2012$0.76$0.74ViewN/AView Earnings Details
10/27/2011$0.17$0.70ViewN/AView Earnings Details
7/28/2011($1.00)($0.67)ViewN/AView Earnings Details
5/3/2011($1.09)($0.91)ViewN/AView Earnings Details
2/3/2011($0.93)($0.74)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
2017 EPS Consensus Estimate: $0.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($0.02)$0.04$0.02
Q2 20174$0.02$0.11$0.07
Q3 20173$0.08$0.14$0.10
Q4 20173$0.26$0.64$0.41
(Data provided by Zacks Investment Research)

Dividends

Dividend History by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ VRTX)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/29/2013quarterly$0.402/20/20133/13/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Ownership Percentage: 1.80%
Institutional Ownership Percentage: 94.20%
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Institutional Ownership by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Insider Trades by Quarter for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2017Amit SachdevEVPSell28,625$160.93$4,606,621.25View SEC Filing  
7/21/2017Ian F SmithCFOSell133,750$160.98$21,531,075.00View SEC Filing  
7/21/2017Jeffrey ChodakewitzCMOSell46,733$160.96$7,522,143.68View SEC Filing  
7/21/2017Jeffrey M LeidenCEOSell216,624$160.96$34,867,799.04View SEC Filing  
7/21/2017Paul M SilvaSVPSell43,443$161.07$6,997,364.01View SEC Filing  
7/19/2017Michael PariniEVPSell10,829$161.00$1,743,469.00View SEC Filing  
7/17/2017Jeffrey ChodakewitzCMOSell573$129.85$74,404.05View SEC Filing  
7/3/2017Jeffrey ChodakewitzCMOSell3,438$127.80$439,376.40View SEC Filing  
6/21/2017Jeffrey ChodakewitzCMOSell5,157$132.87$685,210.59View SEC Filing  
6/21/2017Paul M SilvaSVPSell2,577$133.36$343,668.72View SEC Filing  
6/5/2017David AltshulerEVPSell7,500$130.00$975,000.00View SEC Filing  
6/2/2017Jeffrey M LeidenCEOSell147,101$129.50$19,049,579.50View SEC Filing  
6/2/2017Sangeeta N BhatiaDirectorSell1,176$128.44$151,045.44View SEC Filing  
6/2/2017Stuart A ArbuckleEVPSell70,969$128.06$9,088,290.14View SEC Filing  
5/2/2017Jeffrey ChodakewitzCMOSell8,979$121.05$1,086,907.95View SEC Filing  
4/28/2017Jeffrey M LeidenCEOSell157,200$119.50$18,785,400.00View SEC Filing  
4/5/2017Jeffrey ChodakewitzCMOSell8,021$114.00$914,394.00View SEC Filing  
4/3/2017Jeffrey ChodakewitzCMOSell2,291$108.85$249,375.35View SEC Filing  
3/29/2017Amit SachdevEVPSell80,500$107.63$8,664,215.00View SEC Filing  
3/29/2017Jeffrey ChodakewitzCMOSell13,750$106.65$1,466,437.50View SEC Filing  
3/29/2017Paul M SilvaSVPSell1,688$106.30$179,434.40View SEC Filing  
1/11/2017Joshua S BogerDirectorSell8,000$82.48$659,840.00View SEC Filing  
1/4/2017Joshua S BogerDirectorSell6,500$77.13$501,345.00View SEC Filing  
12/29/2016Joshua S BogerDirectorSell6,500$74.33$483,145.00View SEC Filing  
12/21/2016Joshua S BogerDirectorSell6,500$74.16$482,040.00View SEC Filing  
12/14/2016Joshua S BogerDirectorSell6,500$77.52$503,880.00View SEC Filing  
11/30/2016Joshua S BogerDirectorSell6,500$83.48$542,620.00View SEC Filing  
11/23/2016Joshua S BogerDirectorSell6,500$86.47$562,055.00View SEC Filing  
11/16/2016Joshua S BogerDirectorSell6,500$91.55$595,075.00View SEC Filing  
11/10/2016Paul M SilvaSVPSell5,062$90.98$460,540.76View SEC Filing  
11/9/2016Joshua S BogerDirectorSell6,500$90.98$591,370.00View SEC Filing  
11/9/2016Stuart A ArbuckleEVPSell1,208$90.00$108,720.00View SEC Filing  
11/2/2016Joshua S BogerDirectorSell6,500$77.75$505,375.00View SEC Filing  
10/26/2016Joshua S BogerDirectorSell6,500$79.26$515,190.00View SEC Filing  
10/19/2016Joshua S BogerDirectorSell6,500$81.84$531,960.00View SEC Filing  
10/12/2016Joshua S BogerDirectorSell6,500$81.14$527,410.00View SEC Filing  
10/5/2016Joshua S BogerDirectorSell6,500$87.44$568,360.00View SEC Filing  
10/3/2016Stuart A ArbuckleEVPSell1,208$86.46$104,443.68View SEC Filing  
9/28/2016Joshua S BogerDirectorSell6,500$88.15$572,975.00View SEC Filing  
9/21/2016Joshua S BogerDirectorSell6,500$90.82$590,330.00View SEC Filing  
9/14/2016Joshua S BogerDirectorSell6,500$92.37$600,405.00View SEC Filing  
9/7/2016Joshua S BogerDirectorSell6,500$95.66$621,790.00View SEC Filing  
8/31/2016Joshua S BogerDirectorSell6,500$94.62$615,030.00View SEC Filing  
8/24/2016Joshua S BogerDirectorSell7,500$100.46$753,450.00View SEC Filing  
8/22/2016Joshua S BogerDirectorSell1,100$100.79$110,869.00View SEC Filing  
8/17/2016Joshua S BogerDirectorSell6,900$99.63$687,447.00View SEC Filing  
8/11/2016Joshua S BogerDirectorSell900$100.19$90,171.00View SEC Filing  
8/10/2016Joshua S BogerDirectorSell7,100$100.24$711,704.00View SEC Filing  
8/3/2016Joshua S BogerDirectorSell47,000$100.66$4,731,020.00View SEC Filing  
7/27/2016Joshua S BogerDirectorSell6,500$95.93$623,545.00View SEC Filing  
7/20/2016Joshua S BogerDirectorSell6,500$90.33$587,145.00View SEC Filing  
7/13/2016Joshua S BogerDirectorSell6,500$88.81$577,265.00View SEC Filing  
7/6/2016Joshua S BogerDirectorSell5,140$88.99$457,408.60View SEC Filing  
6/29/2016Joshua S BogerDirectorSell5,130$84.82$435,126.60View SEC Filing  
6/22/2016Joshua S BogerDirectorSell5,130$86.61$444,309.30View SEC Filing  
6/15/2016Joshua S BogerDirectorSell5,130$91.18$467,753.40View SEC Filing  
6/8/2016Joshua S BogerDirectorSell5,130$94.95$487,093.50View SEC Filing  
6/1/2016Joshua S BogerDirectorSell5,130$93.65$480,424.50View SEC Filing  
5/25/2016Joshua S BogerDirectorSell5,130$89.09$457,031.70View SEC Filing  
5/18/2016Joshua S BogerDirectorSell5,130$81.18$416,453.40View SEC Filing  
5/16/2016Amit SachdevEVPSell117$81.67$9,555.39View SEC Filing  
5/16/2016Ian F SmithCFOSell202$82.06$16,576.12View SEC Filing  
5/11/2016Joshua S BogerDirectorSell5,130$86.50$443,745.00View SEC Filing  
5/9/2016Paul M SilvaSVPSell3,000$87.63$262,890.00View SEC Filing  
5/4/2016Joshua S BogerDirectorSell5,130$81.02$415,632.60View SEC Filing  
4/27/2016Joshua S BogerDirectorSell5,130$83.67$429,227.10View SEC Filing  
4/20/2016Joshua S BogerDirectorSell5,130$84.10$431,433.00View SEC Filing  
4/13/2016Joshua S BogerDirectorSell5,130$84.27$432,305.10View SEC Filing  
4/6/2016Joshua S BogerDirectorSell5,130$89.56$459,442.80View SEC Filing  
3/30/2016Joshua S BogerDirectorSell5,130$78.83$404,397.90View SEC Filing  
3/23/2016Joshua S BogerDirectorSell5,130$81.38$417,479.40View SEC Filing  
3/16/2016Joshua S BogerDirectorSell5,130$79.65$408,604.50View SEC Filing  
3/2/2016Joshua S BogerDirectorSell5,130$91.80$470,934.00View SEC Filing  
2/24/2016Joshua S BogerDirectorSell5,130$85.25$437,332.50View SEC Filing  
2/17/2016Joshua S. BogerDirectorSell5,130$86.93$445,950.90View SEC Filing  
2/10/2016Joshua S. BogerDirectorSell5,130$82.57$423,584.10View SEC Filing  
2/3/2016Ian F. SmithCFOSell12,084$90.84$1,097,710.56View SEC Filing  
2/3/2016Jeffrey M. LeidenCEOSell9,834$90.82$893,123.88View SEC Filing  
2/3/2016Joshua S. BogerDirectorSell5,130$90.81$465,855.30View SEC Filing  
2/3/2016Paul M. SilvaSVPSell5,062$90.82$459,730.84View SEC Filing  
2/3/2016Stuart A. ArbuckleEVPSell6,042$90.82$548,734.44View SEC Filing  
2/2/2016Jeffrey ChodakewitzCMOSell2,375$91.38$217,027.50View SEC Filing  
1/27/2016Joshua S. BogerDirectorSell11,200$93.22$1,044,064.00View SEC Filing  
1/20/2016Joshua S. BogerDirectorSell10,400$93.69$974,376.00View SEC Filing  
1/13/2016Joshua S. BogerDirectorSell10,400$98.41$1,023,464.00View SEC Filing  
1/6/2016Joshua S. BogerDirectorSell10,400$121.96$1,268,384.00View SEC Filing  
1/4/2016Yuchun LeeDirectorSell1,125$122.21$137,486.25View SEC Filing  
12/30/2015Joshua S. BogerDirectorSell10,400$127.15$1,322,360.00View SEC Filing  
12/21/2015Joshua S. BogerDirectorSell10,400$119.26$1,240,304.00View SEC Filing  
12/9/2015Joshua S. BogerDirectorSell10,400$120.80$1,256,320.00View SEC Filing  
12/4/2015Stuart A. ArbuckleEVPSell4,531$123.98$561,753.38View SEC Filing  
12/2/2015Joshua S. BogerDirectorSell10,400$130.91$1,361,464.00View SEC Filing  
12/1/2015David AltshulerEVPSell5,000$131.00$655,000.00View SEC Filing  
12/1/2015Yuchun LeeDirectorSell1,125$129.65$145,856.25View SEC Filing  
11/23/2015Joshua S. BogerDirectorSell10,400$132.18$1,374,672.00View SEC Filing  
11/11/2015Joshua S. BogerDirectorSell10,400$118.59$1,233,336.00View SEC Filing  
11/4/2015Joshua S. BogerDirectorSell10,400$124.23$1,291,992.00View SEC Filing  
11/2/2015Yuchun LeeDirectorSell1,125$126.19$141,963.75View SEC Filing  
10/28/2015Joshua S. BogerDirectorSell10,400$119.01$1,237,704.00View SEC Filing  
10/21/2015Joshua S. BogerDirectorSell10,400$108.82$1,131,728.00View SEC Filing  
10/14/2015Joshua S. BogerDirectorSell10,400$112.62$1,171,248.00View SEC Filing  
10/7/2015Joshua S. BogerDirectorSell10,400$109.61$1,139,944.00View SEC Filing  
10/2/2015Elaine UllianDirectorSell20,000$110.00$2,200,000.00View SEC Filing  
10/1/2015Stuart A. ArbuckleEVPSell12,417$104.71$1,300,184.07View SEC Filing  
10/1/2015Yuchun LeeDirectorSell1,125$104.64$117,720.00View SEC Filing  
9/30/2015Joshua S. BogerDirectorSell10,400$103.14$1,072,656.00View SEC Filing  
9/23/2015Joshua S. BogerDirectorSell10,400$111.89$1,163,656.00View SEC Filing  
9/16/2015Joshua S. BogerDirectorSell10,400$133.24$1,385,696.00View SEC Filing  
9/9/2015Joshua S. BogerDirectorSell10,400$131.41$1,366,664.00View SEC Filing  
9/4/2015Stuart A. ArbuckleEVPSell9,063$125.77$1,139,853.51View SEC Filing  
9/2/2015Joshua S. BogerDirectorSell10,400$125.85$1,308,840.00View SEC Filing  
9/1/2015Yuchun LeeDirectorSell1,125$125.40$141,075.00View SEC Filing  
8/26/2015Joshua S. BogerDirectorSell10,400$124.71$1,296,984.00View SEC Filing  
8/19/2015Joshua S. BogerDirectorSell10,400$139.93$1,455,272.00View SEC Filing  
8/12/2015Joshua S BogerDirectorSell10,400$135.83$1,412,632.00View SEC Filing  
7/22/2015Joshua S BogerDirectorSell10,400$130.92$1,361,568.00View SEC Filing  
7/15/2015Joshua S BogerDirectorSell12,200$133.98$1,634,556.00View SEC Filing  
7/13/2015Paul M SilvaSVPSell1,125$123.79$139,263.75View SEC Filing  
7/8/2015Joshua S BogerDirectorSell11,700$122.74$1,436,058.00View SEC Filing  
7/2/2015Jeffrey ChodakewitzCMOSell2,291$129.36$296,363.76View SEC Filing  
7/1/2015Joshua S BogerDirectorSell11,700$125.60$1,469,520.00View SEC Filing  
6/24/2015Joshua S BogerDirectorSell11,700$130.41$1,525,797.00View SEC Filing  
6/17/2015Joshua S BogerDirectorSell11,700$123.90$1,449,630.00View SEC Filing  
6/10/2015Joshua S BogerDirectorSell11,700$125.02$1,462,734.00View SEC Filing  
5/20/2015Joshua S BogerDirectorSell11,700$126.73$1,482,741.00View SEC Filing  
5/6/2015Joshua S BogerDirectorSell11,700$122.79$1,436,643.00View SEC Filing  
5/5/2015Paul M SilvaSVPSell4,101$123.68$507,211.68View SEC Filing  
4/29/2015Joshua S BogerDirectorSell11,700$124.59$1,457,703.00View SEC Filing  
4/27/2015Paul M SilvaSVPSell1,125$129.74$145,957.50View SEC Filing  
4/27/2015Stuart A ArbuckleEVPSell61,480$129.36$7,953,052.80View SEC Filing  
4/27/2015Terrence C KearneyDirectorSell68,125$129.11$8,795,618.75View SEC Filing  
4/22/2015Joshua S BogerDirectorSell11,700$132.46$1,549,782.00View SEC Filing  
4/15/2015Joshua S BogerDirectorSell11,700$129.25$1,512,225.00View SEC Filing  
4/13/2015Paul M SilvaSVPSell1,125$128.60$144,675.00View SEC Filing  
4/8/2015Joshua S BogerDirectorSell11,700$123.26$1,442,142.00View SEC Filing  
4/6/2015Margaret G McglynnDirectorSell12,500$118.36$1,479,500.00View SEC Filing  
4/2/2015Jeffrey ChodakewitzCMOSell2,291$115.50$264,610.50View SEC Filing  
4/1/2015Joshua S BogerDirectorSell11,700$115.87$1,355,679.00View SEC Filing  
3/25/2015Joshua S BogerDirectorSell11,700$120.76$1,412,892.00View SEC Filing  
3/23/2015Amit SachdevEVPSell17,083$132.28$2,259,739.24View SEC Filing  
3/23/2015Ian F SmithCFOSell6,042$125.67$759,298.14View SEC Filing  
3/23/2015Paul M SilvaSVPSell2,250$125.65$282,712.50View SEC Filing  
3/18/2015Amit SachdevEVPSell12,000$130.00$1,560,000.00View SEC Filing  
2/5/2015Paul M SilvaSVPSell1,688$109.75$185,258.00View SEC Filing  
2/4/2015Joshua S BogerDirectorSell5,700$108.81$620,217.00View SEC Filing  
2/3/2015Paul M SilvaSVPSell2,063$108.89$224,640.07View SEC Filing  
2/2/2015Jeffrey ChodakewitzCMOSell1,188$109.60$130,204.80View SEC Filing  
1/28/2015Joshua S BogerDirectorSell10,688$122.78$1,312,272.64View SEC Filing  
1/26/2015Paul M SilvaSVPSell1,125$125.62$141,322.50View SEC Filing  
1/21/2015Joshua S BogerDirectorSell10,500$125.08$1,313,340.00View SEC Filing  
1/14/2015Joshua S BogerDirectorSell10,500$120.16$1,261,680.00View SEC Filing  
1/9/2015Amit SachdevEVPSell12,000$125.00$1,500,000.00View SEC Filing  
1/9/2015Bruce I SachsDirectorSell9,861$125.04$1,233,019.44View SEC Filing  
1/7/2015Joshua S BogerDirectorSell10,500$119.32$1,252,860.00View SEC Filing  
1/2/2015Jeffrey ChodakewitzCMOSell2,291$122.54$280,739.14View SEC Filing  
12/22/2014Joshua S BogerDirectorSell10,500$117.65$1,235,325.00View SEC Filing  
12/17/2014Joshua S BogerDirectorSell10,500$110.66$1,161,930.00View SEC Filing  
12/15/2014Jeffrey M LeidenCEOSell50,017$114.97$5,750,454.49View SEC Filing  
12/12/2014Paul M SilvaSVPSell2,813$120.08$337,785.04View SEC Filing  
11/28/2014Amit SachdevEVPSell12,000$120.00$1,440,000.00View SEC Filing  
11/28/2014Bruce I SachsDirectorSell10,000$120.03$1,200,300.00View SEC Filing  
11/28/2014Paul M SilvaSVPSell8,164$119.85$978,455.40View SEC Filing  
11/26/2014Joshua S BogerDirectorSell10,500$114.54$1,202,670.00View SEC Filing  
11/6/2014Bruce I SachsDirectorSell9,900$115.21$1,140,579.00View SEC Filing  
11/5/2014Bruce I SachsDirectorSell30,100$112.62$3,389,862.00View SEC Filing  
11/3/2014Joshua S BogerDirectorSell127,411$112.20$14,295,514.20View SEC Filing  
10/29/2014Joshua S BogerDirectorSell10,500$109.44$1,149,120.00View SEC Filing  
10/28/2014Amit SachdevEVPSell12,000$115.00$1,380,000.00View SEC Filing  
10/28/2014David AltshulerDirectorSell2,000$114.75$229,500.00View SEC Filing  
10/28/2014Jeffrey ChodakewitzCMOSell3,438$115.00$395,370.00View SEC Filing  
10/27/2014Paul M SilvaSVPSell1,125$110.03$123,783.75View SEC Filing  
10/13/2014Paul M SilvaSVPSell1,125$107.89$121,376.25View SEC Filing  
10/7/2014Jeffrey ChodakewitzCMOSell3,436$104.26$358,237.36View SEC Filing  
10/6/2014David AltshulerDirectorSell1,405$109.75$154,198.75View SEC Filing  
10/1/2014Elaine UllianDirectorSell5,000$107.74$538,700.00View SEC Filing  
10/1/2014Stuart A ArbuckleEVPSell12,417$107.71$1,337,435.07View SEC Filing  
9/30/2014Amit SachdevSVPSell86,000$112.68$9,690,480.00View SEC Filing  
9/30/2014Ian F SmithCFOSell108,026$112.68$12,172,369.68View SEC Filing  
9/30/2014Jeffrey M LeidenCEOSell200,000$112.69$22,538,000.00View SEC Filing  
9/30/2014Kenneth L HortonEVPSell36,000$112.69$4,056,840.00View SEC Filing  
9/29/2014David AltshulerDirectorSell2,500$114.75$286,875.00View SEC Filing  
9/24/2014Joshua S BogerDirectorSell5,200$109.21$567,892.00View SEC Filing  
9/19/2014David AltshulerDirectorSell5,000$102.25$511,250.00View SEC Filing  
9/19/2014Paul M SilvaSVPSell25,408$99.85$2,536,988.80View SEC Filing  
9/19/2014Stuart A ArbuckleEVPSell55,521$100.00$5,552,100.00View SEC Filing  
9/17/2014Joshua S BogerDirectorSell5,200$93.62$486,824.00View SEC Filing  
9/10/2014Joshua S BogerDirectorSell5,200$94.42$490,984.00View SEC Filing  
9/5/2014David AltshulerDirectorSell2,500$94.75$236,875.00View SEC Filing  
9/3/2014Joshua S BogerDirectorSell5,200$92.79$482,508.00View SEC Filing  
8/27/2014Joshua S BogerDirectorSell5,200$93.31$485,212.00View SEC Filing  
8/20/2014Joshua S BogerDirectorSell5,200$91.51$475,852.00View SEC Filing  
8/13/2014Joshua S BogerDirectorSell5,200$88.00$457,600.00View SEC Filing  
8/6/2014Joshua S BogerDirectorSell5,200$86.54$450,008.00View SEC Filing  
7/31/2014David AltshulerDirectorSell5,000$89.59$447,950.00View SEC Filing  
7/31/2014Paul M SilvaSVPSell2,027$88.97$180,342.19View SEC Filing  
7/30/2014Joshua S BogerDirectorSell5,200$92.17$479,284.00View SEC Filing  
7/15/2014Wayne Joseph RileyDirectorSell4,800$96.65$463,920.00View SEC Filing  
7/1/2014Elaine UllianDirectorSell5,000$95.21$476,050.00View SEC Filing  
7/1/2014Kenneth L HortonEVPSell30,134$95.22$2,869,359.48View SEC Filing  
6/24/2014Megan E PaceSVPSell12,734$98.03$1,248,314.02View SEC Filing  
6/24/2014Wayne Joseph RileyDirectorSell15,000$98.03$1,470,450.00View SEC Filing  
6/16/2014Peter MuellerEVPSell7,500$68.31$512,325.00View SEC Filing  
6/9/2014Elaine UllianDirectorSell2,500$75.00$187,500.00View SEC Filing  
5/14/2014Peter MuellerEVPSell7,500$67.45$505,875.00View SEC Filing  
5/2/2014Megan PaceSVPSell1,000$67.62$67,620.00View SEC Filing  
4/15/2014Peter MuellerEVPSell7,500$61.63$462,225.00View SEC Filing  
4/9/2014Elaine UllianDirectorSell2,500$70.00$175,000.00View SEC Filing  
3/21/2014Bruce SachsDirectorSell8,700$74.59$648,933.00View SEC Filing  
3/17/2014Peter MuellerEVPSell7,500$78.29$587,175.00View SEC Filing  
2/7/2014Jeffrey LeidenCEOSell35,944$80.00$2,875,520.00View SEC Filing  
1/22/2014Bruce SachsDirectorSell8,300$84.47$701,101.00View SEC Filing  
1/21/2014Megan PaceSVPSell1,250$85.00$106,250.00View SEC Filing  
1/16/2014Jeffrey LeidenCEOSell45,000$80.00$3,600,000.00View SEC Filing  
1/15/2014Peter MuellerEVPSell7,500$78.67$590,025.00View SEC Filing  
12/23/2013Bruce SachsDirectorSell8,300$73.02$606,066.00View SEC Filing  
12/16/2013Peter MuellerEVPSell7,500$64.69$485,175.00View SEC Filing  
12/12/2013Jeffrey LeidenCEOSell9,834$65.48$643,930.32View SEC Filing  
12/12/2013Kenneth HortonEVPSell4,532$65.46$296,664.72View SEC Filing  
12/12/2013Megan PaceSVPSell5,083$65.48$332,834.84View SEC Filing  
12/4/2013Joshua BogerDirectorSell1,400$67.48$94,472.00View SEC Filing  
11/25/2013Joshua BogerDirectorSell1,400$66.89$93,646.00View SEC Filing  
11/20/2013Bruce SachsDirectorSell8,300$65.28$541,824.00View SEC Filing  
11/19/2013Joshua BogerDirectorSell1,400$62.31$87,234.00View SEC Filing  
11/5/2013Joshua BogerDirectorSell1,400$65.64$91,896.00View SEC Filing  
10/29/2013Joshua S BogerDirectorSell1,400$75.42$105,588.00View SEC Filing  
10/29/2013Thomas ConnollySVPSell1,688$75.04$126,667.52View SEC Filing  
10/24/2013Bruce I SachsDirectorSell8,300$77.06$639,598.00View SEC Filing  
10/23/2013Joshua S BogerDirectorSell1,400$76.77$107,478.00View SEC Filing  
10/16/2013Joshua S BogerDirectorSell1,400$75.41$105,574.00View SEC Filing  
10/15/2013Peter MuellerEVPSell7,500$73.25$549,375.00View SEC Filing  
10/14/2013Paul SilvaSVPSell1,593$71.87$114,488.91View SEC Filing  
10/9/2013Joshua BogerDirectorSell1,400$72.35$101,290.00View SEC Filing  
9/25/2013Joshua BogerDirectorSell1,400$74.72$104,608.00View SEC Filing  
9/18/2013Joshua BogerDirectorSell1,400$77.43$108,402.00View SEC Filing  
9/16/2013Peter MuellerEVPSell7,500$77.22$579,150.00View SEC Filing  
9/11/2013Joshua BogerDirectorSell1,400$79.61$111,454.00View SEC Filing  
9/4/2013Joshua BogerDirectorSell1,400$75.45$105,630.00View SEC Filing  
8/29/2013Bruce SachsDirectorSell8,300$77.19$640,677.00View SEC Filing  
8/28/2013Joshua BogerDirectorSell1,400$76.24$106,736.00View SEC Filing  
8/21/2013Joshua BogerDirectorSell1,400$76.96$107,744.00View SEC Filing  
8/15/2013Peter MuellerEVPSell7,500$77.41$580,575.00View SEC Filing  
8/14/2013Joshua BogerDirectorSell1,400$77.18$108,052.00View SEC Filing  
8/7/2013Joshua BogerDirectorSell1,400$77.84$108,976.00View SEC Filing  
8/5/2013Paul SilvaSVPSell3,001$78.90$236,778.90View SEC Filing  
7/31/2013Joshua S BogerDirectorSell1,400$80.89$113,246.00View SEC Filing  
7/29/2013Wayne Joseph RileyDirectorSell9,800$80.09$784,882.00View SEC Filing  
7/25/2013Paul M SilvaSVPSell1,125$86.49$97,301.25View SEC Filing  
7/24/2013Bruce I SachsDirectorSell8,300$85.50$709,650.00View SEC Filing  
7/19/2013Amit SachdevSVPSell22,250$88.69$1,973,352.50View SEC Filing  
7/18/2013Joshua S BogerDirectorSell1,400$86.12$120,568.00View SEC Filing  
7/16/2013Paul M SilvaSVPSell2,063$86.25$177,933.75View SEC Filing  
7/15/2013Christiana StamoulisSVPSell1,125$86.35$97,143.75View SEC Filing  
7/15/2013Peter MuellerEVPSell7,500$86.34$647,550.00View SEC Filing  
7/12/2013Megan E PaceSVPSell10,678$85.00$907,630.00View SEC Filing  
7/11/2013Joshua S BogerDirectorSell1,400$83.83$117,362.00View SEC Filing  
7/8/2013Kenneth L HortonEVPSell1,813$80.72$146,345.36View SEC Filing  
7/8/2013Megan E PaceSVPSell28,703$80.89$2,321,785.67View SEC Filing  
7/5/2013Christiana StamoulisSVPSell4,687$81.21$380,631.27View SEC Filing  
7/3/2013Joshua S BogerDirectorSell1,400$80.20$112,280.00View SEC Filing  
7/2/2013Peter MuellerEVPSell122,300$79.80$9,759,540.00View SEC Filing  
6/26/2013Joshua S BogerDirectorSell1,400$78.59$110,026.00View SEC Filing  
6/21/2013Bruce I SachsDirectorSell8,300$75.93$630,219.00View SEC Filing  
6/19/2013Joshua S BogerDirectorSell1,400$79.11$110,754.00View SEC Filing  
6/12/2013Joshua S BogerDirectorSell1,400$81.19$113,666.00View SEC Filing  
6/5/2013Joshua S BogerDirectorSell1,400$77.15$108,010.00View SEC Filing  
5/30/2013Joshua S BogerDirectorSell1,400$82.47$115,458.00View SEC Filing  
5/22/2013Joshua S BogerDirectorSell1,400$79.72$111,608.00View SEC Filing  
5/15/2013Joshua S BogerDirectorSell1,400$79.36$111,104.00View SEC Filing  
5/14/2013Bruce I SachsDirectorSell60,000$81.15$4,869,000.00View SEC Filing  
12/26/2012Joshua S BogerDirectorSell4,000$41.86$167,440.00View SEC Filing  
11/7/2012Margaret G McglynnDirectorBuy1,000$45.50$45,500.00View SEC Filing  
10/8/2012Ian F SmithCFOSell44,787$60.00$2,687,220.00View SEC Filing  
10/3/2012Joshua S BogerDirectorSell4,000$57.74$230,960.00View SEC Filing  
9/5/2012Joshua S BogerDirectorSell4,000$54.70$218,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Latest Headlines for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
Source:
DateHeadline
streetinsider.com logoVertex Pharma (VRTX), Concert Pharmaceuticals (CNCE) Complete Asset Purchase Agreement for CTP-656 - StreetInsider.com
www.streetinsider.com - July 26 at 9:50 AM
nasdaq.com logoWhy Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season - Nasdaq
www.nasdaq.com - July 26 at 9:50 AM
finance.yahoo.com logoGilead Faces 6th Quarter of Falling Revenue
finance.yahoo.com - July 26 at 9:50 AM
finance.yahoo.com logoVertex Pharmaceuticals: Robust Growth Trends for Kalydeco in 2017
finance.yahoo.com - July 26 at 9:50 AM
finance.yahoo.com logoWhy Vertex Pharmaceuticals Could Expand Its Addressable Market
finance.yahoo.com - July 26 at 9:50 AM
zacks.com logoWhy Vertex Pharmaceuticals (VRTX) Might Surprise This Earnings Season
www.zacks.com - July 25 at 8:20 AM
finance.yahoo.com logoVertex Energy, Inc. to Release Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 25 at 8:19 AM
americanbankingnews.com logoJMP Securities Reiterates Outperform Rating for Vertex Pharmaceuticals Incorporated (VRTX)
www.americanbankingnews.com - July 24 at 12:28 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Given a $195.00 Price Target by Maxim Group Analysts
www.americanbankingnews.com - July 23 at 3:49 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Given a $175.00 Price Target by J P Morgan Chase & Co Analysts
www.americanbankingnews.com - July 23 at 3:49 PM
finance.yahoo.com logoIs a Beat in the Cards for Vertex (VRTX) in Q2 Earnings?
finance.yahoo.com - July 23 at 9:34 AM
americanbankingnews.com logoMorgan Stanley Reiterates Overweight Rating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
www.americanbankingnews.com - July 22 at 9:32 AM
americanbankingnews.com logoJeffrey M. Leiden Sells 216,624 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
www.americanbankingnews.com - July 22 at 7:23 AM
americanbankingnews.com logoIan F. Smith Sells 133,750 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
www.americanbankingnews.com - July 22 at 7:23 AM
americanbankingnews.com logoMichael Parini Sells 10,829 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
www.americanbankingnews.com - July 22 at 7:22 AM
americanbankingnews.com logoPaul M. Silva Sells 43,443 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stock
www.americanbankingnews.com - July 22 at 7:22 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) EVP Amit Sachdev Sells 28,625 Shares
www.americanbankingnews.com - July 22 at 7:22 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) CMO Jeffrey Chodakewitz Sells 46,733 Shares
www.americanbankingnews.com - July 22 at 7:22 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Receives Outperform Rating from Robert W. Baird
www.americanbankingnews.com - July 21 at 1:44 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Earns Buy Rating from Needham & Company LLC
www.americanbankingnews.com - July 21 at 1:44 PM
americanbankingnews.com logoVertex Pharmaceuticals' (VRTX) "Outperform" Rating Reaffirmed at BMO Capital Markets
www.americanbankingnews.com - July 21 at 12:31 PM
americanbankingnews.com logoCitigroup Inc. Reaffirms Buy Rating for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)
www.americanbankingnews.com - July 21 at 12:30 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Vertex Pharmaceuticals Incorporated Reduced by Leerink Swann (NASDAQ:VRTX)
www.americanbankingnews.com - July 21 at 9:04 AM
investorplace.com logoBuy Vertex Pharmaceuticals Incorporated (VRTX) Stock Like Its 20% Gain Never Happened
investorplace.com - July 20 at 10:03 AM
zacks.com logoVertex (VRTX) Triple Combination CF Studies Data Positive
www.zacks.com - July 19 at 9:24 PM
rttnews.com logoVertex Pharmaceuticals Inc. (VRTX) Is Surging To A New High On Study Results
www.rttnews.com - July 19 at 9:24 PM
seekingalpha.com logoVertex Pharmaceuticals (VRTX) Phase 1 And 2 Data For Triple Combination Regimens Demonstrate Improvements In Lung Function And Other Measures In CF Pa
seekingalpha.com - July 19 at 9:24 PM
finance.yahoo.com logoMaxim Hikes Price Targets on 2 Biotech Stocks: AEterna Zentaris Inc. (USA) (AEZS), Vertex Pharmaceuticals Incorporated (VRTX)
finance.yahoo.com - July 19 at 9:24 PM
finance.yahoo.com logoVertex Pharmaceuticals Stock Is Soaring: Here's Why It's Still Not Too Late to Buy
finance.yahoo.com - July 19 at 9:24 PM
finance.yahoo.com logoGLOBAL MARKETS-World stocks tally 9th day of gains as earnings pick up
finance.yahoo.com - July 19 at 9:24 PM
finance.yahoo.com logo[$$] Vertex Shares Haven’t Hit Their Apex
finance.yahoo.com - July 19 at 9:24 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) CMO Sells $74,404.05 in Stock
www.americanbankingnews.com - July 19 at 8:01 PM
benzinga.com logoMid-Morning Market Update: Markets Rise; Morgan Stanley Beats Q2 Estimates - Benzinga
www.benzinga.com - July 19 at 4:20 PM
benzinga.com logoMid-Day Market Update: Crude Oil Up Over 1%; Cyclacel Pharma Shares Plummet - Benzinga
www.benzinga.com - July 19 at 4:20 PM
nasdaq.com logoPre-Market Most Active for Jul 19, 2017 : MT, VRTX, RAD, BFR, SNI, MS, BABA, SNY, TVIX, MU, QQQ, FB - Nasdaq
www.nasdaq.com - July 19 at 4:20 PM
finance.yahoo.com logoUS STOCKS-S&P, Nasdaq at records as Vertex rallies; IBM slips
finance.yahoo.com - July 19 at 4:20 PM
fool.com logoWhy Vertex Pharmaceuticals Incorporated Stock Is Soaring Today
www.fool.com - July 19 at 2:21 PM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Downgraded to "Neutral" at UBS AG
www.americanbankingnews.com - July 19 at 1:15 PM
americanbankingnews.com logoCredit Suisse Group Boosts Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target to $195.00
www.americanbankingnews.com - July 19 at 10:48 AM
latimes.com logoLed by healthcare companies, stocks open higher
www.latimes.com - July 19 at 10:35 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Raised to Outperform at Raymond James Financial, Inc.
www.americanbankingnews.com - July 19 at 10:25 AM
rttnews.com logoVertex Pharmaceuticals Inc. (VRTX) Is Climbing On Study Results
www.rttnews.com - July 19 at 9:20 AM
finance.yahoo.com logoVertex Pharmaceuticals Stock Surging on Positive Trial Data
finance.yahoo.com - July 19 at 9:20 AM
finance.yahoo.com logoVertex Catapults 24% On Strong Trial For Cystic Fibrosis Drug
finance.yahoo.com - July 19 at 9:20 AM
finance.yahoo.com logoVertex Reports Positive Data for New Cystic-Fibrosis Drugs
finance.yahoo.com - July 19 at 9:19 AM
finance.yahoo.com logoVertex shares soar on positive cystic fibrosis trials
finance.yahoo.com - July 19 at 9:19 AM
finance.yahoo.com logoVertex Pharma shares surge 26% after cystic fibrosis study results leaves Wall Street 'speechless'
finance.yahoo.com - July 19 at 9:19 AM
americanbankingnews.com logoVertex Pharmaceuticals' (VRTX) Buy Rating Reiterated at Jefferies Group LLC
www.americanbankingnews.com - July 19 at 8:54 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Given "Hold" Rating at HC Wainwright
www.americanbankingnews.com - July 19 at 8:53 AM
americanbankingnews.com logoVertex Pharmaceuticals Incorporated (VRTX) Upgraded to "Buy" at Janney Montgomery Scott
www.americanbankingnews.com - July 19 at 8:53 AM

Social

Chart

Vertex Pharmaceuticals Incorporated (VRTX) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff